Triad of Costimulatory Molecules (B7-1, ICAM-1, and LFA-3) (TRICOM)

TRICOM, or the Triad of Costimulatory Molecules, is a therapeutic target complex consisting of three distinct cell-surface proteins: B7-1 (CD80), Intercellular Adhesion Molecule-1 (ICAM-1/CD54), and Lymphocyte Function-associated Antigen-3 (LFA-3/CD58). These molecules are essential for the second signal in T-cell activation, working in concert with the primary signal from the T-cell receptor to ensure a robust and sustained immune response. B7-1 binds to CD28, ICAM-1 binds to LFA-1, and LFA-3 binds to CD2 on the T-cell surface, creating a synergistic effect that significantly lowers the threshold for activation and enhances the production of effector cytokines like interferon-gamma (Hodge et al., 1999). In the context of cancer immunotherapy, TRICOM is typically delivered via recombinant viral vectors (such as vaccinia or fowlpox) to antigen-presenting cells, often in combination with tumor-associated antigens like Prostate-Specific Antigen (PSA) or Carcinoembryonic Antigen (CEA). This strategy, exemplified by the vaccine PROSTVAC-VF, aims to overcome the immunosuppressive tumor microenvironment by providing potent costimulation to tumor-specific T-cells. Clinical studies have demonstrated that TRICOM-based vaccines can induce measurable immune responses and improve overall survival in patients with advanced malignancies, particularly prostate and colorectal cancers, while maintaining a manageable safety profile (Madan et al., 2010; Gulley et al., 2005).

Other names

B7-1/ICAM-1/LFA-3CD80/CD54/CD58T-cell costimulatory triadTRICOM vector

TRICOM acts by providing three distinct costimulatory signals (B7-1/CD28, ICAM-1/LFA-1, and LFA-3/CD2) that synergistically lower the threshold for T-cell activation and enhance the magnitude and duration of the T-cell response against specific antigens (Hodge et al., 1999; Madan et al., 2010).